Unicycive OLC received a second FDA CRL over third-party manufacturing deficiencies. The case shows why CMC risk now drives ...
AlzeCure licensed NeuroRestore ACD856 to QuantumCell in a deal worth over $2.2B. The real story is not proof, but Alzheimer’s ...
Reuters reported that Viridian plans to launch Lumvoa immediately as its first commercial product, and that the company expects to price the drug at parity with the existing approved IGF-1R therapy on ...
Viridian’s Lumvoa Broke Tepezza’s Monopoly. Now Viridian Has to Prove It Can Sell | Witfire Elite View Witfire Elite Competitive Strategy Case Studies Launch Execution Long Read Pharma Market Case ...
FDA gave Sobi a Complete Response Letter for NASP in uncontrolled gout, but the letter did not attack the clinical case. It attacked manufacturing control, CMC readiness and contract manufacturing ...
4SigHT is formally a long-term observational study. Strategically, its timing points to something larger: Tanabe is building a Japanese real-world evidence moat before Bristol Myers Squibb brings a ...
Phase 3 Data, Capital Structure and the Cost of Independence Revolution Medicines has not eliminated acquisition interest. It has eliminated the financial urgency that could force it to accept an ...
Four months after FDA refused to file Moderna’s application, its vaccine advisers unanimously supported its benefit-risk profile in adults aged 50–64 and again in adults aged 65 and older. Same ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results